Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® ...

A startup called Marine Biologics is breaking down seaweed into its base components so they can be used for a range of consumer applications, from foodstuffs to cosmetics to bioplastics.

US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis: Basel Thursday, March 6, 2025, 09:00 Hrs [IST] Roche announced that the US Food and Drug Admini ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Ocugen Inc (OCGN) outlines pivotal trial progress and financial strategies while navigating increased expenses and market ...

Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...

Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. , a commercial-stage biotechnology platform company developing universally implantable, bioengineered human ...

Ocugen, Inc.'s stock dropped 2.8% during Wednesday's session but bounced back in extended trading after the company posted a ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

The sequence contained a promising new genetic tool for modifying DNA, a CRISPR. Editas Medicine, a Massachusetts-based ...